Abstract
TAKAHASHI, H., TAKIZAWA, S., HANANO, M., TATEWAKI, W., NAGASAKI, Y., SASAGAWA, Y. and SHIBATA, A. Evaluation of Fibrinolytic Therapy by Measuring Cross-Linked Fibrin Derivatives and Plasmin-α2-Plasmin Inhibitor Complex in Plasma. Tohoku J. exp. Med., 1987, 153 (4), 295-302 - Plasma levels of α2-plasmin inhibitor (α2PI), plasmin-α2PI complex and cross-linked fibrin derivatives (XDP) were measured in 8 patients (12 episodes) with thromboembolic disorders on the initial administration of urokinase. In conjunction with a decrease in plasma α2PI activity and antigen, plasmin-α2PI complex increased following urokinase infusion in all cases except one who received a low dose (60, 000 units) of urokinase. However, changes in XDP were variable among the patients. Plasma XDP level increased markedly in one, moderately in 4, slightly in one, and remained unchanged in 6 cases (episodes). The increment of plasma XDP correlated (r=0.804, p=0.003) with the dose of urokinase administered, but was independent of changes in plasmin-α2PI complex. The plasma XDP elevation was associated with clinical improvement. These results suggest that simultaneous measurements of XDP and plasmin-α2PI complex in plasma would be valuable for the pharmacological or hemostatic assessment of thrombolytic therapy.
